update regarding company operations

Postal Address 8 Dalgleish Street Telephone +61 8 8234 2660
PO Box 259 Thebarton SA 5031 Facsimile +61 8 8234 6268
Rundle Mall SA 5000 Australia www.bresagen.com.au Email [email protected]
BresaGen Limited
ACN 007 988 767
ABN 60 007 988 767
ASX Release 1st February 2005
BresaGen Update Regarding Company Operations
BresaGen is pleased to announce that it has made significant progress in procuring third party
contracts for its protein engineering business in the 3 months since it emerged from voluntary
administration.
The Company’s protEcol Contract Services business unit has been in discussions with 12
Australian and overseas companies regarding process development and manufacture of their
biologics. As of the end of January, BresaGen has achieved a significant milestone in having
signed contracts totalling $547,000. The Company has a high level of confidence that a
number of other contracts will be executed shortly.
In addition, a collaboration agreement has been executed with an undisclosed overseas
pharmaceutical company. Commencement of the initial project in the collaboration, valued
at $1.2 million, is subject to finalisation of commercial terms.
The Company’s API supply business has also seen an increased demand for its equine and
human growth hormone products over the same period.
The increasing interest in BresaGen’s capability and capacity in the area of protein
expression and process development reflects the level of external confidence and market need
for the Company’s services.
For further information contact:
Dr Wolf Hanisch
Managing Director
BresaGen Limited
Mobile number 0412 339 460